Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Tuesday, BidAskClub reports.

Other equities analysts also recently issued reports about the stock. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals to $90.00 in a research note on Thursday, May 16th. Cowen restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, May 16th. ValuEngine upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 1st. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, February 12th. Finally, Oppenheimer restated a “market perform” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, February 20th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $86.14.

Agios Pharmaceuticals stock opened at $48.70 on Tuesday. Agios Pharmaceuticals has a one year low of $41.63 and a one year high of $99.82. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.89 and a quick ratio of 6.86. The stock has a market cap of $2.86 billion, a PE ratio of -8.08 and a beta of 2.33.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.15. Agios Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 48.19%. The company had revenue of $30.20 million during the quarter, compared to the consensus estimate of $22.69 million. During the same period in the prior year, the business posted ($1.63) EPS. The company’s quarterly revenue was up 243.2% on a year-over-year basis. On average, sell-side analysts expect that Agios Pharmaceuticals will post -6.76 earnings per share for the current fiscal year.

In related news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $67.71, for a total value of $203,130.00. Following the completion of the sale, the insider now directly owns 29,511 shares in the company, valued at approximately $1,998,189.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Bowden sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $64.16, for a total transaction of $641,600.00. The disclosure for this sale can be found here. Insiders sold a total of 23,000 shares of company stock valued at $1,510,430 over the last quarter. 3.16% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of AGIO. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Agios Pharmaceuticals by 14.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 430 shares during the period. Quantamental Technologies LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $28,000. Xact Kapitalforvaltning AB grew its holdings in Agios Pharmaceuticals by 70.3% during the fourth quarter. Xact Kapitalforvaltning AB now owns 13,323 shares of the biopharmaceutical company’s stock worth $614,000 after acquiring an additional 5,500 shares during the period. SG Americas Securities LLC acquired a new position in Agios Pharmaceuticals during the fourth quarter worth $188,000. Finally, State Board of Administration of Florida Retirement System grew its holdings in Agios Pharmaceuticals by 9.7% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 73,397 shares of the biopharmaceutical company’s stock worth $3,384,000 after acquiring an additional 6,461 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Recommended Story: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.